Licensed Producers Are Going Global, But This One Stands Out
Ryan Allway
October 11th, 2017
Exclusive, News, Top News
Canadian licensed producers are well-positioned to become leaders in the global cannabis industry. In mid-2016, Canopy Growth Corp. (TSX: WEED) kicked things off with the first Canadian export to a major G7 country. Aurora Cannabis Inc. (CSE: ACB) and The Cronos Group (CSE: MJN) have since staked their claim in Germany’s market, while Canopy Growth and Tilray have targeted South American markets, like Brazil.
Harvest One Cannabis Inc. (TSX-V: HVST) has made tremendous progress in growing its international footprint. The company’s wholly-owned United Greeneries subsidiary is awaiting approval from Health Canada for its ACMPR license to sell, but its wholly-owned Satipharm AG business has established an impressive presence in Europe, Australia, Canada, and Israel.
Satipharm’s CBD Capsules
Satipharm AG is a Swiss firm specializing in developing medical cannabis brands leveraging its oral delivery technologies. The company’s flagship Gelpell-CBD Microgel Capsules are available in either 10mg, 50mg, or 100mg doses of cannabidiol (“CBD”) and available in a growing number of markets around the world. The established legal status of CBD means that these products can be sold in a wide array of markets that are off limits to THC-based brands.
The capsules are produced with cannabis extracts from its partner – AI FAME GMBH / Ai LABS SWISS AG – and fulfills all criteria of the European Pharmacopoeia with 92% purified CBD and no THC or other cannabinoids. Once extracted, the cannabinoids are processed under an exclusive technology use agreement by Gelpell AG, which substantially enhances the bioavailability of the cannabinoids after consumption. Bioavailability is one of the vexing issues surrounding cannabinoid therapies as the active ingredients are degraded by metabolic processes in the body. Gelpell’s micro-bead technology ensures delivery and dose accuracy under these conditions.
These capsules are available over-the-counter and are being used in two separate Phase 2 clinical trials being conducted through PhytoTech Therapeutics. The company also received approval for the manufacturing of THC-based products in Switzerland with the goal of developing new formulations to offer medical cannabis patients in Canada and Australia by the first half of next year – opening the door to even more opportunity.
Expanding Presence in Europe
Satipharm announced earlier this year that its Gelpell-CBD Microgel Capsules were available in all pharmacies throughout Germany. The company also announced that it signed a letter of intent with a leading pharmaceutical distributor and retailer in Denmark for distribution throughout Scandinavia. The company anticipates that the partnership will provide direct access to hundreds of thousands of potential customers through targeted campaigns.
More recently, the company announced that it received a “Free Sale Certificate” from German authorities that reduces constraints for international exports and removes regulatory trading impediments with other EU jurisdictions. The company’s CBD capsules are considered a “food supplement”, which makes it the only company in Europe with a GMP-grade nutraceutical CBD product. Management expects to see an increase in demand across Europe as a result.
The company has also been actively expanding its distribution network with a focus on Germany, Denmark, the UK, Ireland, the Netherlands, Spain, and Austria. In these countries, the company’s CBD capsules are available in several online shops, on Amazon, in mail order pharmacies, and in conventional brick-and-mortar pharmacies. Sales have started to rise in the months following the expansion with “sizable contracts” already in place.
Looking Ahead
Satipharm has successfully developed several key marketing channels throughout Europe and Australia. With United Greeneries applying to become a licensed dealer Harvest One could soon expand into Canada as well. The approval of United Greeneries as a licensed dealer could similarly enable it to access international markets through relationships that Satipharm has built over the past several years.
Investors may want to take a closer look at Harvest One Cannabis Inc. (TSX-V: HVST) given these developments and the potential moving forward.
For more information, visit the company’s website at www.harvestone.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
Amercanex was founded with the sole-purpose to ensure a completely transparent, neutral, and non-manipulated marketplace for cannabis industry participants.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
